Introduction
2017 represents the 200th anniversary of the publication of The Shaking Palsy by James Parkinson and the 20th anniversary of the discovery of the first unequivocal cause of Parkinson disease (PD)-a mutation in the α-synuclein gene (Polymeropoulos and others 1997) . These two anniversaries reflect the accelerating pace of progress in understanding the causes of and developing new treatments for this and other neurodegenerative diseases, particularly given that more than 20 Parkinsonrelated genes have been described just in the last 20 years. This review focuses on a recent and exciting observation that mutations in the glucocerebrosidase (GBA) gene are the most common genetic association with PD and dementia with Lewy bodies. We have attempted to provide a brief overview of clinical features, epidemiology, and pathology of PD in order to provide a background to provide a detailed review of the contribution of GBA gene mutations to PD and how our understanding of this relationship is providing invaluable insights into the design of novel therapies that might be used to slow the progress of PD.
types of tremor such as postural ("re-emergent") or kinetic tremor can be detected. Sometimes patients refer to an "internal tremor," which is not detectable with neurological examination.
Bradykinesia, hypokinesia, and akinesia are commonly used synonymously, even though they refer to different disturbances of voluntary movement execution and they do not always coexist in individual patients. Bradykinesia can simplistically be defined as slowness in movements (especially repetitive ones) with progressive reduction in amplitude and speed, with the loss of the fluidity of voluntary movements-although PD patients can show difficulties not only in executing but also in planning and initiating movement.
Rigidity refers to an increased resistance to passive movements, due to a continuous and uniform increase in muscle tone. Two types of parkinsonian rigidity are classically recognized: the "lead pipe" rigidity, which is uniform throughout range of movement and is not dependent on passive movement velocity, and the "cog-wheel" rigidity, in which the rigidity is regularly interrupted by tremor during passive movements. Rigidity must be differentiated from other forms of hypertonia, such as spasticity and paratonia.
Postural instability usually occurs in the later stages of the disease; it is one of the strongest determinants of quality of life, disability and risk of falls and fractures, and consequently morbidity and mortality, in PD. Postural instability is determined by different causes such as impaired postural reflexes, lack of control of voluntary movements, orthostatic hypotension, age-related sensory changes and weakening of leg muscles, and dyskinesias and other parkinsonian symptoms.
PD is characterized by other motor features, such as postural abnormalities (camptocormia and Pisa syndrome), freezing of gait, festination, micrographia, hypomimia, alteration of blinking and eye movements, and others.
Non-motor features
Even if motor symptoms have historically been recognized as the defining features of PD, non-motor symptoms (NMS) are an integral part of the clinical picture (Chaudhuri and others 2006; Schapira and others 2017) . NMS in PD cover a wide variety of manifestations, including autonomic, gastrointestinal, sleep, sensory, cognitive, and neuropsychiatric disturbances, disturbances of speech, dysphagia, and sialorrhea; their frequency and/or severity usually increase in later stages of the disease, but they can also appear in early stages. NMS may be misdiagnosed, but when properly assessed they are found to affect the majority of PD patients and have a severe impact on health-related quality of life and disability. Some NMS might arise before the emergence of motor symptoms: depression, constipation, and rapid eye movement behavior sleep disorder (RBD) can precede PD diagnosis and are therefore called "prodromal" or "premotor" symptoms.
Epidemiology and Risk Factors
PD is the second most common neurodegenerative disease in the general population (de Rijk and others 1997). In industrialized countries, its prevalence is estimated to be 0.3% in the general population and to be 3-and 10-fold higher in the over-60-and over-80-year-old populations respectively. The incidence rates range between 8 and 18 per 100,000 person-year, rising up to 121 cases/100,000 person-years in people aged 40 to 85 and 200 per 100,000 in people aged 60-84 years (Lee and Gilbert 2016) . Age is considered to be the most important risk factor for PD. Men have a higher risk of developing PD, have an earlier onset and show different clinical features (Gillies and others 2014) . Different risk/protective factors have been 
Motor Symptoms
Non-motor Symptoms linked to PD: Their mechanism of action will be further explained in specific sections of this article. Risk factors include pesticides, herbicides, insecticides, fungicides or paraquat exposure, rural living, farming, and well-water consumption (Breckenridge and others 2016) ; exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and annonacin have been found as causative factors in two particular forms of parkinsonism (Champy and others 2004; Langston and Palfreman 1996) . Protective factors include caffeine consumption, cigarette smoking, use of calcium channel blockers, and statins, while contrasting evidence is available regarding use of non-steroidal anti-inflammatory drugs (NSAIDS), uric acid levels, or gout (Kalia and Lang 2015) .
Pathology
Loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) with the accumulation of α-synuclein in Lewy bodies (LB) and Lewy neurites are the pathological hallmarks of PD (Fig. 1a) . It is suggested that at the time of motor symptoms and diagnosis dopaminergic neurons in the SNc are reduced up to 60% (Marsden 1990) . LB are composed of more than 90 different proteins, of which the most abundant is α-synuclein (Spillantini and others 1997; Wakabayashi and others 2013) . Besides the SNc, LB are widely distributed in different structures of the central nervous system; it has been proposed that LB and α-synuclein accumulation follows a sequential pattern of deposition, starting in the dorsal motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus and progressively spreads to the brain stem. In later stages, the involvement spreads to the cortex, firstly to the mesocortex and allocortex and finally to the neocortex (Fig. 1b ) (Braak and others 2003) . α-Synuclein pathology in PD has been found in structures other than the brain: LB-like aggregates have been found in the olfactory epithelium, in dorsal root ganglia, cranial and spinal nerves, in the enteric nervous system, the adrenal gland, in skin nerves and other structures; however, LB-like structures are also found in peripheral structures in healthy elderly subjects (Longhena and others 2017) . (b) Hypothesized pattern of Lewy bodies and α-synuclein deposition: starting in the dorsal motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus and progressively spread to the brain stem. In later stages, the involvement spreads first to the mesocortex and allocortex and finally to the neocortex (Braak and others 2003) . BFB = basal forebrain; BN = brainstem nuclei; DMX = dorsal motor nucleus of the vagus nerve; MTC = mesiotemporal cortex; OB = olfactory bulb; SN = substantia nigra. Reprinted from Schapira and others (2017) , Nature Reviews Neuroscience, with permission from SpringerNature, copyright 2017.
The deposition of LB and α-synuclein is accompanied by microglial activation and elevation of inflammatory cytokine levels, suggesting that inflammation could contribute to neurodegeneration: A current hypothesis is that there is a positive feedback loop between microglia activation, neuro-inflammation and α-synuclein deposition, which contributes to neurodegeneration (Zhang and others 2017) .
Pathogenesis

α-Synuclein
α-Synuclein is a 140-amino acid presynaptic protein, whose main role is thought related to neurotransmitter release through the SNARE complex (Burré and others 2010) . The pathogenicity of α-synuclein seems to be related to its accumulation, misfolding, and aggregation more than a loss of function. Knockout or depletion of the α-synuclein gene (SNCA) in animal models do not cause a parkinsonian phenotype (Abeliovich and others 2000) , although there is an impairment in vesicle trafficking (Murphy and others 2000) ; SNCA knockout has been shown to be protective against PD-related neurodegeneration (Luk and others 2012) .
The pathogenicity of α-synuclein relies on its tendency to misfold and accumulate. In its native state, α-synuclein is a folded tetramer of 58 kDa (Bartels and others 2011; Wang and others 2011) , but it can acquire oligomeric and aggregated conformations, which are the most abundant forms in LB. The accumulation and aggregation of α-synuclein is a stepwise process: Misfolded monomers aggregate first into dimers and then in oligomers that are stabilized by β-sheet-like interactions; these aggregates become insoluble protofibrils and finally amyloid-like structures.
The oligomeric and protofibrillar forms are considered more toxic than the β-sheet-rich amyloid aggregate, their toxicity is mediated through a number of mechanisms including mitochondrial (Hsu and others 2000) , lysosomal (Chu and others 2009) , and proteasomal (Snyder and others 2003) dysfunction, damage to biological membranes (Danzer and others 2007) and the cytoskeleton (Alim and others 2004) and the disruption of synaptic function (Scott and others 2010) . It has been suggested that LB may represent an attempt to limit the toxicity of these forms, thereby constituting a neuroprotective factor and an epiphenomenon to neurodegeneration more than a factor contributing to it (Ding and others 2002; Lashuel and others 2002a; Lashuel and others 2002b) .
The first insight to the role of α-synuclein in the pathogenesis of PD came from the discovery of its mutation (A53T) in an autosomal dominant form of PD (Polymeropoulos and others 1997) ; this mutation, results in more rapid oligomerization than the wild-type (Conway and others 2000) ; other pathogenic mutations of SNCA affect the quantity of α-synuclein, such as duplications (Chartier-Harlin and others 2004; Ibáñez and others 2004) , triplications (Singleton and others 2003) , and mutations in promoter regions (Pals and others 2004) ; moreover, higher levels of α-synuclein mRNA have been found in sporadic PD (Chiba-Falek and others 2006). However, it is not only the production of α-synuclein that determines its accumulation; other mechanisms, such as changes in its turnover via the ubiquination-proteasome pathway and autophagy, can contribute-as will be discussed in the following section of this review. Oligomeric or fibrillar α-synuclein has the ability to spread to other cells; it was found in grafted neurons in the brains of PD patients that had received fetal implants; this finding was reproduced in vitro and in vivo and then α-synuclein has been demonstrated to spread also when inoculated in the absence of other pathogenic circumstances (Brundin and others 2016) .
Endoplasmic Reticulum Stress
The accumulation of misfolded proteins in the cell leads to a condition known as endoplasmic reticulum (ER) stress: when misfolded proteins accumulate in the ER, a feedback mechanism up-regulates the transcription of chaperones and other stress-induced proteins; this process is called unfolded protein response (UPR) and in both physiological and pathological conditions, it maintains the homeostasis of the ER and recycles the unfolded proteins through ER-associated degradation (ERAD); misfolded or unassembled polypeptides are retro-translocated into the cytosol for degradation by the ubiquitin proteasomal or lysosomal systems (Zhang and Ye 2014) ; however, if the misfolded protein load and ER stress are irreversible, the apoptosis pathway is activated (Hetz 2012) . As well for other neurodegenerative diseases (Matus and others 2011) , an increase in ER stress is thought to be linked with PD pathogenesis: ER stress markers (Colla and others 2012a) together with α-synuclein deposition in the ER (Colla and others 2012b) have been found both in in vivo and autopsy studies (Hoozemans and others 2007) .
One of the genes implicated in PD pathogenesis plays a regulatory role in ER stress and associated neurodegeneration (Yuan and others 2011): mutations in LRKK2 cause a familial form of PD, characterized by relatively late onset, variable penetrance and pleomorphic pathological features (Funayama and others 2002) . The physiological role of this protein is still debated, and may include protection of the cell in the case of ER stress (Dächsel and others 2010) .
Disturbances of Autophagy and Lysosomal Function
There is increasing evidence that defects in autophagy and lysosomal pathways play a key role in the pathogenesis of PD.
Autophagy is a process that allows the cell to degrade and recycle, through the lysosomes, cytosolic molecules or organelles. It is enhanced in response to cell injury, starvation or hormonal signaling; alternatively, autophagy can prime cell death. Three different kinds of autophagy are known: microautophagy, macroautophagy, and chaperone-mediated autophagy (CMA); even though the three pathways are distinct, they all culminate in the lysosome (Galluzzi and others 2017) . In macroautophagy (autophagy) the cargo to be directed to the lysosome is transported in a double-membrane vesicle (autophagosome). The autophagosome then fuses its membrane with the lysosome forming the autolysosome or, in case of convergence with the endocytic pathway, an amphisome. After degradation, all the products of this process are transferred back to the cytosol to be recycled for energy production or biosynthesis of cell components. The term microautophagy refers to a process where cytosolic molecules are sequestered directly by the lysosomal membrane into intra-lysosomal vesicles, it is constitutively active and regulates the turnover of cell components; however, the details about the regulation of this mechanism still have to be outlined. In CMA, proteins that are "marked" by a specific peptide sequence (KFERQ-like) are transported to the lysosome by a cytosolic chaperone (HSC70) though a receptor in the lysosomal membrane, the lysosome-associated membrane protein (LAMP) type 2A.
In addition to alterations of α-synuclein production and folding, disturbances in its degradation and/or clearance can determine its accumulation (Cuervo and others 2004) . Wild-type α-synuclein is degraded both by autophagy and by the CMA pathway; it contains the pentapeptide sequence 95 VKKDQ 99 , which is recognized by the CMA pathway as well as by the proteasome (Webb and others 2003) . Upregulation or inhibition of autophagy processes respectively decrease or increase the level of α-synuclein in cells. In contrast, mutant (A30P and A53T) α-synuclein are poorly degraded by this pathway and inhibit it, with toxic consequences for the cell.
LRKK2 has been implicated in this network: physiologically, LRKK2 is degraded by CMA; the degradation of mutated forms interferes with CMA, as mutant LRRK2 blocks LAMP-2A oligomerization and slows α-synuclein degradation, contributing to neurodegeneration in PD (Orenstein and others 2013; Yue and Yang 2013) .
Other genes that are more clearly linked to autophagy pathways have been associated with PD (Fig 2) .
Mutations in ATP13A2 (PARK9) cause Kufor-Rakeb syndrome, which is an autosomal recessive form of earlyonset parkinsonism with pyramidal degeneration and dementia (Ramirez and others 2006) . ATP132A is a lysosomal ATPase (Schultheis and others 2004) , which is highly expressed in the brain, and in particular in the substantia nigra. In idiopathic PD (iPD), its expression is upregulated in surviving dopaminergic neurons, suggesting a role in protective mechanisms (Ramirez and others 2006) . Its mutation causes lysosomal dysfunction (Dehay and others 2012; Usenovic and others 2012) and results in parkinsonism and a lysosomal storage disorder (Bras and others 2012) . In case of LRKK2 mutations and consequent lysosomal dysfunction, ATP13A2 is up-regulated, showing a potential "rescue" system activated by the cell (Henry and others 2015) . ATP13A2 shows a close relationship with α-synuclein metabolism: it regulates its exosomal-secretion, accumulation, aggregation and has been demonstrated to be protective in case of α-synuclein overexpression (Kong and others 2014; Lopes da Fonseca and others 2016; Tsunemi and others 2014; Usenovic and others 2012) .
ATP13A2 is linked with other PD pathogenic mechanisms: patients with mutations in ATP13A2 show mitochondrial dysfunction (Grünewald and others 2012; Park and others 2014), while its over-expression reduces oxidative stress in rotenone-induced mitochondrial damage (Holemans and others 2015) .
Other autophagy-related genes have been linked to PD (Gan-Or and others 2015b): Mutations of VPS35, which encodes for a subunit of the retromer complex, have been linked to familial forms of PD with autosomal heritance and low penetrance (Vilariño-Güell and others 2011; Zimprich and others 2011); the same gene has also been linked to Alzheimer's disease (Small and others 2005; Wen and others 2011) . The retromer complex recycles trans-membrane receptors from the endosome via the trans-Golgi network (Pfeffer 2001) , and it is implicated in the homeostasis between protein degradation and accumulation. In PD dopaminergic neurons with mutations of VPS35, both a poor retrieval of LAMP2A and accumulation of α-synuclein have been demonstrated (Tang and others 2015) .
The most important discovery in PD research linking etiology and pathogenesis to lysosomal function is the recognition that mutations of the gene for glucocerebrosidase represent the most important risk factor identified to date for the development of PD. This relationship will be the main focus of the present review.
Mitochondrial Dysfunction
A direct link between mitochondrial dysfunction and PD came with the discovery of a specific reduction of mitochondrial complex I activity in PD SN (Schapira and others 1989) . Subsequent to this discovery, mutations of genes linked to mitochondrial function and homeostasis were identified in familial forms of PD. Given their fundamental role and the potential for cell damage as a result of mitochondrial dysfunction, "mitochondrial quality" is governed by multiple control pathways, and parts of mitochondria are constantly replaced even under physiological circumstances. The main mechanism for the clearance of damaged mitochondria is mitophagy, a specific form of autophagy (Fig. 3) . Mutations of PINK1 and parkin are causes of autosomal recessive PD (Kitada and others 1994; Valente and others 2004) and these proteins play important roles in mitochondria quality control. When a mitochondrion is damaged, its membrane is depolarized; at this point PINK1, a serine/threonine kinase, accumulates on the outer membrane to "mark it for degradation" and activate the mitophagy pathway through the recruitment of Parkin, which is an E3 ubiquitin ligase. This catalyzes the polyubiquitination and initiates the degradation through the autophagosome-lysosome pathway; other proteins that interact with mitochondria e.g., Mitofusin and Miro are also involved in this process (Ashrafi and Schwarz 2013) .
FBXO7 mutations cause parkinsonian-pyramidal disease, an early-onset form of parkinsonism (Di Fonzo and others 2009 ). This gene (PARK15) encodes for an E3 ubiquitin ligase, which plays important role in targeting proteins for ubiquitination and subsequent degradation (Deng and others 2013) and participates in mitophagy.
Mutations of DJ-1 cause a familial early-onset form of PD (Bonifati and others 2003) : DJ-1 plays a crucial role in regulating calcium flux in the mitochondrion (Ottolini and others 2013) protecting the cell by oxidative stress produced by the pace-making activity of dopaminergic neurons (Guzman and others 2010) and dopamine toxicity (Lev and others 2009) and its deficiency causes an increased sensitivity to oxidative stress (Kim and others 2005) .
There is a strong relationship between mitochondrial impairment and α-synuclein accumulation, accumulation is associated with altered morphology and function of mitochondria and an increase in oxidative stress in a vicious circle, since oxidative stress increases the accumulation of α-synuclein. Increased activity of the PINK1/ parkin pathway is neuro-protective in models of α-synuclein overexpression (Schapira and Gegg 2011) .
GBA: Activity and Regulation
Glucocerebrosidase (GCase; glucosylceramidase; EC 3.2.1.45) is a lysosomal enzyme that metabolises glucosylceramide (GlcCer) to glucose and ceramide. GCase is encoded by the GBA gene, which is located on chromosome1q21, comprises 11 exons and encodes a 497-amino acid protein of approximately 62 kDa, which can be divided into three domains: Domain 1 (an antiparallel B-sheet), Domain 2 (containing the active site of the protein, a triose phosphate isomerase barrel), and Domain 3 (an 8-stranded B-barrel); there is a homologue pseudogene on the same chromosome. GBA transcription is modulated by the transcription factor EB (TFEB), which regulates the expression of a network of genes implicated in lysosomemediated degradative pathways, named CLEAR (coordinated lysosomal expression and regulation). TFEB colocalizes with mTORcomplex1 on the lysosomal membrane, and is important for the regulation of lysosomal biogenesis and activity, for lipid metabolism, autophagy, and Ca ++ homeostasis in the lysosome. After its translation, GCase is translocated into the ER for post-translational modifications. GCase then binds to LIMP2 in the ER, is transported through the trans-Golgi network and finally localizes in the membrane of the lysosome after a pHdependent dissociation from LIMP2; in LIMP2 knock-out mice there is a reduction in GCase activity and an accumulation of the inactive enzyme. Under pathological circumstances, GCase co-localizes in the lysosome with a co-chaperone named Progranulin (PGRN), which is implicated in numerous cellular pathways, from inflammation and wound healing to aging. Glucocerebrosidase is activated by Saposin-C in the lysosome, but the mechanism by which this enzyme promotes lysosomal GCase hydrolysis is still undefined (Smith and others 2017) .
GBA and PD
Defects in glucocerebrosidase cause autosomal recessive Gaucher disease (GD), which is the most common lysosomal storage disease worldwide, and has a particularly high prevalence among Ashkenazi Jews. Pathogenesis of GD is complex and includes deficits in macrophage function, cytokine and chemokine production and an imbalance between pro-and anti-inflammatory signaling and impaired regulation of inflammatory cascades (Grabowski 2012) .
It has been shown that obligate or confirmed carriers of GBA mutations have a higher risk of developing parkinsonism (Goker-Alpan and others 2004). Definitive confirmation of the association between PD and GBA came from a large multicenter study, conducted on 5691 patients and 4898 controls, which found that GBA mutations were significantly prevalent among a heterogeneous population of PD patients with an odds ratio of 5.43 (Sidransky and others 2009) . Even if the proportion of PD patients with GBA mutations varies depending on the population studied (more common in Ashkenazi) and sequencing method, between 5% and 25% of PD patients carry GBA mutations Schapira 2015) . Heterozygous mutations of GBA confer a 10% to 30% chance of developing PD by age 80 years: a 20-fold increase compared with non-carriers; GD patients and asymptomatic heterozygous gene mutation carriers are at almost equal risk for development of PD (Alcalay and others 2012; Anheim and others 2012; Higuero and others 2013; Rana and others 2013). A study conducted on data from a web-based assessment of PD prodromal markers to estimate the risk of PD showed that in the "high risk of PD group" the odds ratio of having a GBA variant was 9.5 times greater than in other groups (Noyce and others 2015) . GBA mutations increase the risk of other synucleinopathies: this was demonstrated in Lewy body dementia (Goker-Alpan and others 2006; Nalls and others 2013), while discordant evidence is available on multi-system atrophy (Jamrozik and others 2010; Mitsui and others 2015; Segarane and others 2009). ; there may be some association with the specific mutation in GBA (Gan-Or and others 2015a; Lesage and others 2011), for example, those with the L444P mutation have a more aggressive course (Brockmann and others 2014; Winder-Rhodes and others 2013). There is contrasting evidence on the occurrence of levodopa-induced dyskinesias, since one study reported that levodopa-induced dyskinesias were more severe in PD with GBA mutations than in controls (Lesage and others 2011), but no difference was observed in another recent study (Zhang and others 2015) . The risk for dyskinesia in the GBA group most likely relates to the age of onset, as in young-onset PD. Non-motor symptoms have been found in PD patients who carry a GBA mutation: enteric, sexual, and urinary dysfunctions, orthostatic hypotension, fatigue, pain, RBD and others seem to be more common in this population (Brockmann and 
GBA-PD Clinical Features
Is There a Genotype-Phenotype Correlation in GBA-PD?
Different GBA mutations have been suggested to result in different risks of developing PD: the odds ratios for PD ranged between 2.84 and 4.94 for mild mutation carriers and 9.92 and 21.29 for severe GBA mutation carriers (Gan-Or and others 2015a). A study demonstrated that the most prevalent PD-associated GBA mutation is E326K, which interestingly has not been described in GD . Some clinical features associated with specific GBA mutations have been identified: E236K has been associated with rapid motor progression, postural and gait instability but not tremor, wearing off or dyskinesia (Davis and others 2016; Oeda and others 2015) , and with a higher risk or a more aggressive evolution of cognitive deterioration even though in the same domains as other PD patients (Davis and others 2016; Mata and others 2015; Winder-Rhodes and others 2013) . GBA mutations linked to neuropathic GD (such as L444P, 84GG, G195E, H255Q, R257Q, P266L, R359X, G377S, D409H, L444R, A456P, N462K, R120W, and R463C) and complex alleles (E326K plus D140H mutations, E326K plus T369M, E326K plus R463C, E326K plus R257Q; and homozygotes carriers with E326K/E326K, T369M/T369M, and E326/E326K/L444P/L444P) but not those of non-neuropathic GD (N370S) have been associated with a more rapid cognitive decline (Liu and others 2016) . The risk of dementia in carriers of "severe" mutations (p.L444P, p.G377S, splicing mutation IVS10+1G>T) has been estimated to be 5.6 times higher than in iPD and 2.9 times higher than "mild" GBA mutations (p.N370S) (Cilia and others 2016) . No differences between mild and severe GBA mutations were found for the development of hallucinations (Barrett and others 2014) .
Studies have demonstrated that some prodromal signs of PD (impairment of olfaction, cognition, and subtle motor signs) (McNeill and others 2012b) and thinning of the retinal ganglion cell layer (McNeill and others 2013b) were more frequent in asymptomatic GBA mutation carriers at baseline. A longitudinal study of the asymptomatic carriers of GBA mutations showed significant worsening of depression and motor signs and significant differences in smell, autonomic dysfunction, cognition and motor signs in comparison with controls (Beavan and others 2015) .
Non-Clinical Biomarkers
Imaging does not differentiate GBA-PD from other forms of PD: fluorodopa PET or single-photon emission computerized tomography (SPECT) with dopamine-sensitive ligands in PD-GBA patients shows asymmetric tracer loss in the posterior putamen, as seen in iPD (Goker-Alpan and others 2012; McNeill and others 2013c) (Fig. 4) . In another study, both transcranial sonography (TCS) and positron emission tomography in GBA-PD did not show any difference when compared with iPD or LRRK2-PD; however, this study was conducted on a small sample (Barrett and others 2013) ; the findings on TCS were confirmed in another study . Discriminant features were identified in other brain regions using different techniques: a reduction of parietal and precuneus blood flow has been observed in GBA-PD. This finding is consistent with current knowledge on GBA. This pattern of cerebral blood flow is seen in Lewy body dementia (Goker-Alpan and others 2012; Oeda and others 2015) .
White matter abnormalities involving the interhemispheric, frontal corticocortical, and parahippocampal tracts have been found in GBA-PD when compared with other PD patients (Agosta and others 2013) . A functional magnetic resonance imaging (MRI) study found a significant decrease in cerebral metabolic rates of glucose in the supplemental motor area in patients with a GBA mutation, with additional hypometabolism in the parieto-occipital cortices in those who had parkinsonian signs (Kono and , together with a with reduction in the heart to mediastinum ratio, the degree of which correlated with the stage of PD and dementia ; however, this has not been confirmed by all studies (Oeda and others 2015) .
Different methods of studying GCase activity in PD have been attempted: a reduction of GCase activity has been demonstrated in the cerebrospinal fluid (CSF) of PD patients with and without GBA mutations Parnetti and others 2017) and Lewy body dementia patients (Parnetti and others 2009), although not consistently (van Dijk and others 2013). The authors also found that a combination of β-glucocerebrosidase activity, oligomeric/total α-synuclein ratio, and age can discriminate PD from neurological controls with a sensitivity of 82% and a specificity of 71% . However, comparison between different studies must be carried out with caution, given the high number of factors that influence lysosomal enzymes levels measurement in CSF . A reduction of GCase activity has also been demonstrated in blood samples from patients with GBA mutations and non-GBA-PD (Alcalay and others 2015) .
Another way to assess GCase activity is to measure intermediates and products of its metabolic pathways (Fig. 5) : GBA-PD patients show lower levels of fatty acids (omega-3 and omega-6) in the CSF (Schmid and others 2012) , measurement of fatty acids in the plasma of iPD patients demonstrated higher levels of all lipid species in PD patients versus controls, and higher levels of ceramide and monohexosylceramide were found in those with cognitive impairment (Mielke and others 2013) .
Pathophysiology of GBA in non-GBA mutation PD
There is evidence that GCase activity might play a role in the pathogenesis of PD, even in those patients without GBA-mutations. A significant reduction in substantia nigra and striatum GCase activity was identified in iPD brain and was related to the abnormal accumulation of α-synuclein, alterations in lysosomal autophagy and CMA and lipid metabolism (Gegg and others 2012) and was confirmed in a further study (Murphy and others 2014) . A decline in GCase activity has also been seen in aging healthy controls (Rocha and others 2015) . Decreased GCase activity was found in the substantia nigra and cerebellum of sporadic PD brains; there appears to be a relationship between α-synuclein and GCase levels in brain (Schapira and Gegg 2013) . α-Synuclein accumulation occurs in response to inhibition of GCase with Conduritol B Epoxide (CBE) in SH-SY5Y cells and mice (Cleeter and others 2013; Manning-Boğ and others 2009) , GBA KD in primary neurons, (Mazzulli and others 2011) , in induced pluripotent stem cells (iPSCs) from GBA-PD patients (Schöndorf and others 2014) , in the brain of mouse models of GCase deficiency, in dopaminergic neurons generated from iPS from reprogrammed fibroblasts of a GD patient (Cullen and others 2011; Mazzulli and others 2011; Osellame and others 2013; Sardi and others 2011) and in a neural crest stem cell-derived dopaminergic neuronal model (Yang and others 2017) . Heterozygosity for GBA mutation worsens α-synuclein accumulation, as well as clinical manifestations, in a α-synuclein mutation mouse (Fishbein and others 2014) . For an extensive review of models of GBA-PD, see (O'Regan and others 2017; Siebert and others 2014) .
It is proposed that, in neurons, deficient GCase leads to accumulation of glucocerebroside which promotes aggregation of toxic α-synuclein oligomers through their stabilization, and causes a decline in lysosomal proteolysis that selectively affects α-synuclein (Mazzulli and others 2011) . In fact, tau-which is another aggregation-prone protein involved in neurodegenerative diseases-does not accumulate; this finding is consistent with the selective role for GBA in synucleinopathies. Increase of α-synuclein has also been demonstrated in the E326K mutation, the hypothesis is that this variant reduces GCase activity enough to induce the accumulation of α-synuclein, but not of glucosylceramide .
Similar effects can occur in mutations of other genes that are important for GCase function. LIMP-2 deficiency causes a reduction in GCase activity and impaired autophagic/lysosomal function, lipid storage, and α-synuclein accumulation with consequent neurodegeneration, inflammation and apoptosis, while its overexpression in cell lines reduces α-synuclein levels (Rothaug and others 2014) . TFEB down-regulation results in a marked potentiation of α-synuclein toxicity and a modification of its subcellular localization, with the reduction of its nuclear levels and subsequent inactivity, has been found in the midbrain of PD patients. It has been proposed that this could be secondary to the accumulation of α-synuclein, which sequestrates TFEB it in the cytosol (Decressac and others 2013) .
On the other hand, an increased level of α-synuclein may reduce GCase activity through several different pathways. Biophysical studies revealed that, at a low pH, α-synuclein in its membrane-bound α-helical form selectively interacts with and inhibits GCase (Yap and others 2011; Yap and others 2015) (Fig. 6) . Moreover, overexpression of α-synuclein leads to the downregulation of lysosome-resident glucocerebrosidase, inhibiting ER-toGolgi and ER-to-lysosome trafficking (Chung and others 2013; Cooper and others 2006; Mazzulli and others 2016; Thayanidhi and others 2010) .
Finally, it has been demonstrated that in mice with increased alpha-synuclein expression, the L444P GBA mutation enhances neuronal vulnerability to neurodegenerative processes (Migdalska-Richards and others 2017b).
In-vitro studies demonstrated that increasing the activity of glucocerebrosidase reduces α-synuclein accumulation. Adeno-associated virus-mediated expression of exogenous GCase in GBA mutated (D409V/D409V) mice improved clinical and pathological features Yang and others 2017) ; overexpression of glucocerebrosidase in the CNS of A53T α-synuclein mice reduced the levels of soluble α-synuclein (Sardi and others 2013) and the use of ambroxol to increase GCase activity lowered α-synuclein levels in overexpression mice (Migdalska-Richards and others 2016).
However, the relevance of GCase to PD is not limited to its interaction with α-synuclein. As already explained, in physiological conditions wild-type glucocerebrosidase is folded in the endoplasmic reticulum and translocated to the lysosomes. Misfolded GCase is arrested in the endoplasmic reticulum and undergoes polyubiquitination and degradation-causing ER stress-and triggers the UPR and ERAD (Bendikov-Bar and others 2011; Mu and others 2008; Ron and Horowitz 2005) . Evidence for these processes was confirmed in studies conducted on iPSC derived from GBA-mutations carriers (Fernandes and others 2016) and increased ERAD markers were found in GBA-PD brains (Gegg and others 2012) . A study suggested that parkin could play a determinant role in GCase degradation (Ron and others 2010) ; however, a further study performed on fibroblasts carrying biallelic parkin mutations demonstrated that parkin is not a fundamental E3-ubiquitin ligase for glucocerebrosidase (McNeill and others 2013a) .
A growing body of evidence suggests that GCase could interfere with mitochondrial function, another key mechanism in PD pathogenesis. Impairment in mitochondria function and morphology together with a reduced production of ATP and an increase in oxidative stress has been demonstrated in GCase inhibition (Cleeter and others 2013) , in fibroblasts from GD patients and in mice models of GD (de la Mata and others 2015; Xu and others 2014) . For a review of mechanism of mitochondrial dysfunction in GCase deficiency, see Gegg and Schapira (2016) .
Therapeutic Implications
Given the reciprocal relationship between glucocerebrosidase deficiency and α-synuclein deposition, several strategies are under investigation to enhance GCase function in order to slow, stop, or reverse PD's neurodegenerative processes. There are two approved therapies for patients with GD: enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), the effects of which are-respectively-to enhance glucocerebroside degradation or to inhibit its production. ERT (mannose-terminal human glucocerebrosidase) is currently accepted as the first line therapy for GD and offers good results in GD type 1 patients (Shemesh and others 2015) but is ineffective in neurological symptoms, since the enzyme does not pass the BBB (Schueler and others 2002) ; at the moment, a peptide-linked recombinant glucocerebrosidase that targets neurons is in development (Gramlich and others 2016) . SRT (Cox and others 2000) is used as a second-line treatment because of the more common side effects (Shemesh and others 2015) . SRT crosses the blood-brain barrier and therefore has been tested in GD type 3 in a randomized, controlled trial; however, it did not show significant benefits for the neurological features (Schiffmann and others 2008) .
Another strategy to treat GD is the use of small molecule chaperones, whose function is to facilitate correct folding and translocation of GCase, increasing its lysosomal levels and activity and preventing glycolipid accumulation. The most studied among these compounds is ambroxol (ABX); this drug was initially used to treat airway mucus hypersecretion and hyaline membrane disease in infants, and was then recognised as a pH-dependent, mixed-type inhibitor of GCase (Maegawa and others 2009) . ABX acts as a chaperone for GCase and enhances lysosomal function and autophagy through the activation of the CLEAR network via TFEB, LIMP2, and Sap-C upregulation (Ambrosi and others 2015; McNeill and others 2014) . Importantly, ABX also shows antioxidant properties (Stetinová and others 2004) , is administrable orally and crosses the blood-brain barrier (Luan and others 2013) . ABX improves trafficking of GCase to the lysosome and increases GCase activity in GD fibroblasts (1) Agents that reduce expression of wild-type α-synuclein and thus reduce the natural substrate for a prion or templating reaction; (2) up-regulation of chaperones that promote refolding or clearance of abnormal proteins; (3) facilitation of UPS or autophagy/lysosomal function to promote clearance of unwanted proteins; (4) interference with the prion conformer whereby misfolded α-synuclein acts as a template to promote the conversion of wild-type α-synuclein; (5) agents or immune approaches targeted to remove toxic α-synuclein oligomers or aggregates; (6) increased glucocerebrosidase stability or trafficking through the endoplasmic reticulum to normalise α-synuclein metabolism and lysosomal function. These interventions (1-6) are designed to prevent or reduce the toxic effects of α-synuclein oligomers or aggregates on vital cell processes (e.g., mitochondrial function and axonal transport). intervention (7) represents agents that prevent release of α-synuclein from affected cells and/or the uptake of α-synuclein into healthy unaffected cells whereby the process might extend throughout the nervous system. Dashed arrows represent inhibition and solid arrows represent pathways of progression. UPS = ubiquitin proteasome system. Reprinted from Schapira and others (2014) , The Lancet, with permission from Elsevier, copyright 2014 (https://www.sciencedirect.com/science/article/pii/S0140673614610102).
(Bendikov-Bar and others 2011; Maegawa and others 2009), and a recent pilot study in GD type 1 patients highdose oral ABX was safe and well tolerated and improved some neurological features (Narita and others 2016) .
ABX increased GCase activity and lysosomal function in fibroblasts from GBA-PD, GBA mutations healthy carriers and in controls, and reduced α-synuclein accumulation in a neuronal cell line . ABX treatment decreased α-synuclein levels and improved autophagy also in neural crest stem cell-derived dopaminergic neurons (Yang and others 2017) . Experiments in GBA mutant Drosophila demonstrated that ABX and isofagomine (see next section) improve GCase function, decreased ER stress and reversed the motor phenotype (SanchezMartinez and others 2016). In wild-type mice, transgenic mice expressing the heterozygous GBA L444P and transgenic mice overexpressing human α-synuclein, ABX increased in GCase activity and decreased α-synuclein and phosphorylated α-synuclein protein levels (in the mice overexpressing human α-synuclein) (Migdalska-Richards and others 2016). In healthy non-human primates, the daily, oral administration of ABX resulted in a 20% increase in GCase activity in the midbrain, cortex, and striatum -similar to the mouse model (Migdalska-Richards and others 2017a). There are two clinical trials of ABX currently underway in PD and PD dementia.
Other small-molecule non-inhibitory chaperones of glucocerebrosidase are under evaluation.
The iminosugar isofagomine (IFG) is an active-site inhibitor that facilitates the folding and transport of newly synthesized GlcCerase and has been shown to increase GCase activity and reduce substrate accumulation in cell and mouse models (Khanna and others 2010; Steet and others 2006; Sun and others 2012) of GD; although it was not successful in reducing the accumulation of lipid substrates in a model of neuropathic GD . Its efficacy was tested in a fly model of GBA-PD (Sanchez-Martinez and others 2016). Oral administration of isofagomine in mice that overexpress human wild-type α-synuclein improved motor and olfactory performance, reduced microglial activation and reduced α-synuclein immunoreactivity in nigral DA neurons (Richter and others 2014) . NCGC607, which was tested in iPSCs differentiated into dopaminergic neurons-from patients with GD1, GD with parkinsonism, and GD2-enhanced GCase function, reduced glycolipids storage and the accumulation of α-synuclein (Aflaki and others 2016) .
Finally, given that autophagy is a fundamental process in PD and the pathogenesis of other neurodegenerative diseases, the possibility of enhancing this process using targets and pathways other than GCase has been extensively studied: the most studied compound for this aim is rapamycin, which regulates autophagy through a mTor-dependent network. Rapamycin has been shown to reduce α-synuclein accumulation and the consequent neurodegeneration in both cellular and animal models of PD. The application of autophagy-modulating agents in PD is further discussed in a recent review by Moors and others (2017) .
Conclusion
Mutations of GBA are the most common genetic association with PD discovered to date and approximately 10% of PD patients carry such mutations. At present, they constitute a risk factor as only a minority of those that carry the mutations develop PD or a synucleinopathy. Evidence from a variety of in vitro and in vivo models indicate that GCase activity and α-synuclein levels have a reciprocal relationship, although the molecular mechanisms underlying this are not fully understood. Nevertheless, the therapeutic potential to manipulate this connection to enhance GCase and so reduce α-synuclein has been recognized and clinical trials are already underway evaluating the actions of ABX in PD patients with and without GBA mutations, and in PD dementia, and the use of SRT in PD. These trials represent translational studies targeting the GCase pathway that offer the potential to modify the natural course of PD.
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